Page 1

CENTURY THERAPEUTICS Century Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business Updates November 10 , 2021 Lead program , CNTY - 101 in relapsed / refractory non - Hodgkin's lymphoma , remains on track for IND filing in mid - 2022 Pre - clinical data from CNTY - 101 program and CAR - IT platform to be presented at the ASH Annual Meeting Research and development update to be held on Thursday , December 16 , 8 : 00-9 : 30 AM EST Made significant investment in building in - house manufacturing facility and new laboratory space Ended third quarter with cash , cash equivalents , and marketable securities of $ 400.3M PHILADELPHIA , Nov. 10 , 2021 ( GLOBE NEWSWIRE ) -- Century Therapeutics , Inc. , ( NASDAQ : IPSC ) , an innovative biotechnology company developing induced pluripotent stem cell ( iPSC ) -derived cell therapies in immuno - oncology , today reported financial results and business highlights for the third quarter ended September 30 , 2021 . " We continue to deepen investments in cellular reprogramming , genetic engineering , and manufacturing , in order to advance our iPSC platforms , with an ultimate goal of developing therapies that can meaningfully advance cancer care , " said Lalo Flores , Chief Executive Officer , Century Therapeutics . " We are making tangible progress in advancing our lead candidate , CNTY - 101 , into the clinic , with our IND filing on track for mid - 2022 . Additionally , through our recently announced collaboration with Outpace Bio , we are further investing in new technologies as we execute on our vision of building a next - generation cell therapy platform . We expect to provide scientific updates on our programs later this year and at our upcoming virtual research and development update . " Business Highlights • Entered into a research collaboration agreement with Outpace Bio to explore Outpace's protein solutions for cell therapy to potentially enhance the functionality of Century's iPSC platform . The collaboration's initial program will focus on hematological malignancies with an option to expand to additional candidates . • Included in the small - cap Russell 2000Ⓡ Index as a part of the 3Q21 Russell Indexes IPO additions . Upcoming Milestones • Pre - clinical data from the Company's CNTY - 101 program and CAR - iT platform to be presented in two posters at the upcoming American Society of Hematology ( ASH ) Annual Meeting and Exposition on December 11-14 , 2021 in Atlanta , Georgia , and virtually . • Virtual research and development update to be held on Thursday , December 16 , 2021 from 8 : 00-9 : 30 AM EST . Century's management team will discuss an update on the Company's iPSC technology platform and pipeline . Eduardo Sotomayor , M.D. , Director of the Cancer Institute at Tampa General Hospital , will discuss the current treatment paradigm for B - cell malignancies . For additional information on how to access the event , please visit the Events & Presentations section of Century's website . • Current Good Manufacturing Practice ( cGMP ) manufacturing facility expected to be operational in early 2022 . • CNTY - 101 IND filing remains on track for mid - 2022 . Third Quarter 2021 Financial Results • Cash Position : Cash , cash equivalents , and marketable securities were $ 400.3 million as of September 30 , 2021 , as compared to $ 440.0 million as of June 30 , 2021 . • Research and Development ( R & D ) expenses : R & D expenses were $ 19.5 million for the three months ended September 30 , 2021 , compared to $ 10.8 million for the same period in 2020. The increase in R & D expenses was primarily due to an increase in personnel expenses related to increased headcount to expand the Company's research and development capabilities , costs for preclinical studies , costs for laboratory supplies , and facility costs . • General and Administrative ( G & A ) expenses : G & A expenses were $ 6.3 million for the three months ended September 30 , 2021 , compared to $ 2.3 million for the same period in 2020. The increase was primarily due to an increase in personnel related expense due to an increase in employee headcount and an increase in the Company's professional fees as a result of expanded operations to support the Company's infrastructure as well as additional costs to operate as a public company .